Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of S80880 in CD123-positive acute leukemias and other hematologic malignancies
NL-OMON42264Phase 1Withdrawn
- Sponsor
- Servier
- Start
- Jan 2015
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flotetuzumab in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute leukemia of ambiguous lineage (ALAL) and 3 more, sponsored by Servier. Primary endpoint: Dose-limiting toxicity during cycle 1. Planned start Jan 2015; status: withdrawn.
02
Drugs
flotetuzumab
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)acute leukemia of ambiguous lineage (ALAL)myelodysplastic syndrome (MDS)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NL-OMON42264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42264.